Name | Deflazacort |
Synonyms | deflan calcort azacort Denazacort Deflazacort 11b,21-Dihydroxy-2'- DEFLAZACORT INTERMEDIATE 16-d)oxazole-3,20-dione,11-beta,21-dihydroxy-2'-5'-beta-h-pregna-4-dieno(17 (11β,16β)-11-hydroxy-2-methyl-5β-H-progna-1,4-dieno[17,16-d]Oxazolo-3,20-dione (5'β)-21-Acetyloxy-11β-hydroxy-2'-methylpregnano[17,16-d]oxazole-1,4-diene-3,20-dione 11b,21-Dihydroxy-2'-methyl-5'bH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate (5'β)-11β-Hydroxy-21-acetyloxy-2'-methyl-1,2,4,5-tetradehydropregnano[17,16-d]oxazole-3,20-dione (4AR,4BS,5S,6AS,9AR,10AS,10BS)-6B-ACETYL-5-HYDROXY-4A,6A,8-TRIMETHYL-4A,4B,5,6,6A,6B,9A,10,10A,10B,11,12-DODECAHYDRO-9-OXA-7-AZA-PENTALENO[2,1-A]PHENANTHREN-2-ONE |
CAS | 14484-47-0 13649-88-2 |
EINECS | 238-483-7 |
InChI | InChI=1/C23H29NO4/c1-12(25)23-19(28-13(2)24-23)10-17-16-6-5-14-9-15(26)7-8-21(14,3)20(16)18(27)11-22(17,23)4/h7-9,16-20,27H,5-6,10-11H2,1-4H3/t16-,17-,18-,19+,20+,21-,22-,23?/m0/s1 |
Molecular Formula | C25H31NO6 |
Molar Mass | 441.52 |
Density | 1.41 |
Melting Point | 255-256.5°C |
Boling Point | 595.4±50.0 °C(Predicted) |
Specific Rotation(α) | D +62.3° (c = 0.5 in chloroform) |
Flash Point | 282.9°C |
Solubility | DMSO: ≥20mg/mL |
Vapor Presure | 4.13E-14mmHg at 25°C |
Appearance | powder |
Color | white to tan |
Merck | 14,2862 |
pKa | 14.30±0.70(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.675 |
Physical and Chemical Properties | Acetone-hexane crystals, melting point 255-256.5 °c. [Α] D 62.3 °(C = 0.5, chloroform). UV maximum absorption (methanol):241~242nm(E1 cm152.5). Acute toxicity LD50 mice (mg/kg):5200 oral; 1610 subcutaneous injection. Acute toxicity LD50 rats (mg/kg):109 subcutaneous injection. Acute toxicity LD50 dog (mg/kg):>4000 oral; 50 subcutaneous. |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | TU4157050 |
HS Code | 29349990 |
Toxicity | LD50 orally in mice: 5200 mg/kg (Schiatti) |
crystallized from acetone-hexane, melting point 255-256.5 °c.
3-hydroxy-2 '-methyl -5' H-nonando [17,16-d] n-oxazole-11, 20-= ketoxane in methanol, the aqueous solution of semicarbazide hydrochloride and pyridine was added, and the compound obtained by the reaction was dissolved in 95% ethanol. The aqueous solution of potassium carbonate and sodium borohydride were added, and the refluxing reaction was carried out. Should be. The reduced product was dissolved in methanol-hydrochloric acid and hydrolyzed under reflux. The product obtained by hydrolysis was dissolved in anhydrous toluene and cyclohexanone, and the reaction was carried out by adding triisopropylaluminum. The reaction product is dissolved in anhydrous dioxane, heated together with the acetic acid solution of hydrogen bromide, and the bromine dioxane solution is added. After the reaction, the reaction solution is put into water, and the obtained crystal is dried and then dissolved in dimethylformamide, A mixture of lithium bromide and lithium carbonate was added and reacted by heating to obtain a 1, 4-diene compound. The compound is dissolved in a mixed solution of tetrahydrofuran and methanol, added with calcium oxide and azobisisobutyronitrile, and then added with iodine in a mixed solution of tetrahydrofuran methanol, and iodination reaction is carried out. The resulting iodinated product was dissolved in acetone, triethylamine, acetone and acetic acid were added, and the reaction gave divot.
Gruppo Lepetit S. p. A. Third-generation glucocorticoids. Anti-inflammatory, anti-allergic, increased gluconeogenesis and other effects. For primary and secondary adrenal hypofunction, rheumatism, collagen disease, skin disease, allergic disease, eye disease, fulminant and disseminated tuberculosis, hematopoietic disorders, ulcerative colitis, idiopathic nephrotic syndrome, malignant tumor of hematopoietic system, etc.
mouse oral LD50:5200mg/kg.